针对复发性或耐药性晚期细胞癌的向疗法的选择
1Department of Medicine, Division of Medical Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.
对于晚期细胞癌 (RCC) 复发或对初始治疗没有反应,针对血管内皮生长因子 (VEGF) 或缺氧诱导因子 (HIF) 的疗法是关键. 治疗选择取决于瘤类型和先前的治疗方法.
科学领域:
- 在瘤学瘤学.
- 医学科学 医学科学 医学科学
背景情况:
- 免疫疗法和血管生成向疗法改善了前期细胞癌 (RCC) 治疗.
- 然而,不可切除和转移的RCC通常在初始治疗后进展,长期结果有限.
- 在使用免疫检查点抑制剂 (ICI) 后复发或耐火 (R/R) RCC通常会阻止ICI的再发作.
研究的目的:
- 审查目前针对清晰细胞和非清晰细胞RCC的二线或后期治疗的向疗法.
- 讨论R/R RCC正在研究的新型治疗策略.
主要方法:
- 针对R/R RCC的向治疗方法的文献综述.
- 对当前治疗模式和新兴策略的分析.
主要成果:
- 治疗R/R RCC的重点是抑制VEGF,HIF和mTOR通路.
- 药剂的选择以瘤组织学,先前的治疗和患者的并发症为指导.
结论:
- 有效管理R / R RCC需要仔细选择向疗法.
- 未来对生物标志物的研究可能会预测对免疫,血管新生或基于HIF的治疗的反应.
更多相关视频
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Treatment Resistant Cancers
Inhibition of Cdk Activity
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
